Although promising, together these findings show how essential future studies are in order to more clearly define the role and mechanisms of GPR41 in insulin secretion, as well as the potential druggability of its agonists/antagonists to improve T2D and obesity-related metabolic abnormalities. The gene discussed is INS; the disease is Obesity.